´ëÇѳ»ºÐºñÇÐȸ (¿Â¶óÀÎ) 2021³â Postgraduate Course : 2021-09-25±³À°ÀÏÀÚ : 2021-09-25
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) 2021³â Postgraduate CourseÁÖÃÖ±â°ü : ´ëÇѳ»ºÐºñÇÐȸ
´ã´çÀÚ : È«Áö¼ö
¿¬¶ôó : 02-2038-3771
À̸ÞÀÏ :
endo@endocrinology.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 70,000¿ø
ºñ°í ºÀÁ÷ÀÇ/°³¿øÀÇ 5¸¸¿ø (ºñȸ¿ø 7¸¸¿ø)Àü°øÀÇ ¹× ±âŸ(±âÃÊÀÇÇÐÀÚ/°£È£»ç/¾à»ç µî) 3¸¸¿ø(ºñȸ¿ø 5¸¸¿ø)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-25 09:00~09:25 Áú·®ºÐ¼®¹ý ±âÃÊ ÀÌ·Ð ¿ÀÇѺó(¼°´ë)
±³À°½Ã°£ 09-25 09:25~09:50 ÀÓ»ó½Ã·á ¹Ì·®ºÐ¼®À» À§ÇÑ ½Ã·á °ü¸® ÇÑ»ó¹ü(Áß¾Ó´ë)
±³À°½Ã°£ 09-25 09:50~10:15 ÀÓ»ó½Ã·á ³» steroidogenesis Æò°¡ ±â¼ú ÃÖ¸¸È£(KIST)
±³À°½Ã°£ 09-25 10:15~10:40 ÀÓ»ó°Ë»ç½Ç¿¡¼ÀÇ Áú·®ºÐ¼®¹ý µµÀÔ°ú ¿î¿µ ¹ÚÇüµÎ(¼º±Õ°üÀÇ´ë)
ÈÞ½Ä 09-25 10:40~10:50 Break ()
±³À°½Ã°£ 09-25 10:50~11:15 Approach to the patient with an adrenal incidentaloma ±èÈ¿Á¤(À»ÁöÀÇ´ë)
±³À°½Ã°£ 09-25 11:15~11:40 New drugs for pitutiary diseases ±¸Ã¶·æ(¿¬¼¼ÀÇ´ë)
Åä·Ð 09-25 11:40~12:05 Q&A ¹× Panel Discussion ()
½Ä»ç 09-25 12:05~12:45 Lunch Break ()
±³À°½Ã°£ 09-25 12:45~13:10 Future game changer in diabetes (weekly basal insulin (icodec) and imeglimin) È«ÁØÈ(À»ÁöÀÇ´ë)
±³À°½Ã°£ 09-25 13:10~13:35 SGLT2 inhibitor in chronic kidney disease, where is the lowest limit of eGFR? ±è½Å°ï(°í·ÁÀÇ´ë)
Åä·Ð 09-25 13:35~14:00 Q&A ¹× Panel Discussion ()
ÈÞ½Ä 09-25 14:00~14:10 Break ()
±³À°½Ã°£ 09-25 14:10~14:35 Best treatment option for RAI-refractory advanced thyroid cancer Àü¹ÎÁö(¿ï»êÀÇ´ë)
±³À°½Ã°£ 09-25 14:35~15:00 How to adopt the molecular testing in thyroid nodule diagnosis Á¶¼±¿í(¼¿ïÀÇ´ë)
Åä·Ð 09-25 15:00~15:25 Q&A ¹× Panel Discussion ()
ÈÞ½Ä 09-25 15:25~15:35 Break ()
±³À°½Ã°£ 09-25 15:35~16:00 Mechanisms and therapeutic effects of osteoporosis medications ¹é±âÇö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09-25 16:00~16:25 Management strategies after discontinuation of denosumab ±èºÎ°æ(°í½ÅÀÇ´ë)
Åä·Ð 09-25 16:25~16:50 Q&A ¹× Panel Discussion ()